Table 2

In vitro parameters of GC sensitivity and relative decrease in DAS

Bioassays

GC binding assay



β (95% CI)a

P value

β (95% CI)a

P value



IL-2-EC50

-0.014 (-0.028-0.001)

0.058

KD

0.03 (0.014-0.046)

0.001



Age

0.005 (-0.002-0.110)

0.161

Age

0.009 (0.002-0.017)

0.020

Gender

0.128 (-0.057-0.312)

0.169

Gender

0.199 (0.013-0.385)

0.037

Use of NSAID

0.087 (-0.087-0.261)

0.316

Use of NSAID

0.212 (0.025-0.400)

0.028

Number of DMARDs

0.023 (-0.079-0.125)

0.647

Number of DMARDs

0.112 (0.004-0.221)

0.043

Use of anti-TNF-α

0.008 (-0.283-0.299)

0.955

Use of anti-TNF-α

0.222 (-0.010-0.455)

0.060



GILZ-EC50

-0.023 (-0.046-0.001)

0.062

GR number/1,000

0.027 (0.012-0.042)

0.001



Age

0.006 (-0.001-0.014)

0.079

Age

0.010 (0.002-0.018)

0.015

Gender

0.116 (-0.075-0.308)

0.225

Gender

0.017 (-0.188-0.223)

0.862

Use of NSAID

0.181 (-0.004-0.366)

0.055

Use of NSAID

0.203 (0.006-0.400)

0.044

Number of DMARDs

0.021 (-0.085-0.126)

0.695

Number of DMARDs

0.084 (-0.027-0.195)

0.132

Use of anti-TNF-α

0.023 (-0.270-0.320)

0.874

Use of anti-TNF-α

0.129 (-0.121-0.378)

0.297


In all four models, relative decrease in DAS was the dependent variable. The data represent the combined bioassays from intramuscularly treated patients with early (n = 14) and established RA (n = 31). GILZ-EC50 and IL-2-EC50 were not associated with relative decrease in DAS in orally treated patients in recent-onset RA (n = 22). The GC-binding assay is performed only in established RA (n = 30, all intramuscular GC). aValues represent adjusted β-coefficients and 95% confidence intervals.

Quax et al. Arthritis Research & Therapy 2012 14:R195   doi:10.1186/ar4029

Open Data